Discovery of Rapid-Acting, Orally Available Antidepressants by Activating TrkB Signaling.
Journal of Medicinal Chemistry July 29, 2025 Xu Cheng, Fan Jiang, Lixin Liu et al. 1 citation
Major depressive disorder (MDD) remains a significant global health burden, and its current treatments are limited by the delayed onset of efficacy weeks after dosing. While esketamine and psychedelics were clinically successful as rapid-acting antidepressants in recent years, these molecules are heavily associated with psychotic side effects and the risks of substance abuse. In this study, we...